147 related articles for article (PubMed ID: 19491286)
1. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
Bolin K; Wilson K; Benhaddi H; de Nigris E; Marbaix S; Mork AC; Aubin HJ
Eur J Public Health; 2009 Dec; 19(6):650-4. PubMed ID: 19491286
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
Lock K; Wilson K; Murphy D; Riesco JA
Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of varenicline for smoking cessation.
Keiding H
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
9. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
Vemer P; Rutten-van Mölken MP
Value Health; 2010; 13(2):230-41. PubMed ID: 19804435
[TBL] [Abstract][Full Text] [Related]
10. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims.
Zeng F; Chen CI; Mastey V; Zou KH; Harnett J; Patel BV
Clin Ther; 2011 Feb; 33(2):225-34. PubMed ID: 21497706
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
Higashi H; Barendregt JJ
Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
[TBL] [Abstract][Full Text] [Related]
12. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
[TBL] [Abstract][Full Text] [Related]
13. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
Keating GM; Lyseng-Williamson KA
Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Howard P; Knight C; Boler A; Baker C
Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
[TBL] [Abstract][Full Text] [Related]
15. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
Bolin K; Mörk AC; Willers S; Lindgren B
Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
Knight C; Howard P; Baker CL; Marton JP
Value Health; 2010; 13(2):209-14. PubMed ID: 19912599
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea.
Bae JY; Kim CH; Lee EK
Value Health; 2009; 12 Suppl 3():S70-3. PubMed ID: 20586986
[TBL] [Abstract][Full Text] [Related]
18. The cost effectiveness of varenicline for smoking cessation.
Halpern MT; Dirani R; Schmier JK
Manag Care Interface; 2007 Oct; 20(10):18-25. PubMed ID: 18405203
[TBL] [Abstract][Full Text] [Related]
19. A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities.
Zimovetz EA; Wilson K; Samuel M; Beard SM
J Eval Clin Pract; 2011 Apr; 17(2):288-97. PubMed ID: 21029268
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
Knight C; Marbaix S; Annemans L; Prignot J; Bowrin K
Acta Clin Belg; 2012; 67(6):416-22. PubMed ID: 23340147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
